Clinical Trial Update: AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing osimertinib to placebo in patients with stage IB-IIIA non-small cell lung cancer after complete resection (with or without adjuvant chem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Stage IB-IIIA Non-small Cell Lung Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-07-27